Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Meletios-Athanasios Dimopoulos, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2024-203910

Published: 2024

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Panagiotis Malandrakis, Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Irene Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Kostantina Taouxi, Alexandra Papadimou, Christine-Ivy Liacos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2024-203751

Published: 2024

Journal Articles

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Efstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 7021.

https://doi.org/10.1182/blood-2024-203941

Published: 2024

Journal Articles

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Despina Fotiou, Foteini Theodorakakou, Irene Solia, Maria Gavriatopoulou, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2024-203853

Published: 2024

Journal Articles

Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Efstathios Kastritis, Panagiotis Malandrakis, Irene Solia, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Christine-Ivy Liacos, Nefeli Mavrianou Koutsoukou, Katerina Chrisostomidou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos

Blood (2024) 144 (Supplement 1): 4675.

https://doi.org/10.1182/blood-2024-203858

Published: 2024

Journal Articles

Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Maria Roussou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Irene Solia, Asimina Papanikolaou, Charikleia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4674.

https://doi.org/10.1182/blood-2024-203780

Published: 2024

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

Journal Articles

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Blood (2023) 142 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2023-179416

Published: 2023

Journal Articles

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Tina Bagratuni, Alexandra Papathoma, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2023-189926

Published: 2023

Journal Articles

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Panagiotis Zis, Rodanthi Syrigou, Stella Fanouraki, Maria Gavriatopoulou, Despina Fotiou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 529.

https://doi.org/10.1182/blood-2023-180673

Published: 2023

Journal Articles

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Efstathios Kastritis, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Eirini Solia, Foteini Theodorakakou, Rodanthi Syrigou, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7152–7153.

https://doi.org/10.1182/blood-2022-165924

Published: 2022

Journal Articles

Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

Efstathios Kastritis, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Eirini Solia, Panagiotis Malandrakis, Rodanthi Syrigou, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7324–7325.

https://doi.org/10.1182/blood-2022-165792

Published: 2022

Journal Articles

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Nikolaos Kanellias, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 4275–4276.

https://doi.org/10.1182/blood-2022-165403

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Sosana Delimpasi, Michele Cavo, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Roussou, Despina Fotiou, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Alexandros Leonidakis, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 2729.

https://doi.org/10.1182/blood-2021-153075

Published: 2021

Journal Articles

Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality

Efstathios Kastritis, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Nikolaos Kanellias, Despina Fotiou, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Stavroula Giannouli, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2021-146949

Published: 2021

Journal Articles

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Alexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, Eleni-Dimitra Papanagnou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstathios Kastritis, Meletios-Athanasios Dimopoulos

Blood (2021) 138 (Supplement 1): 3791.

https://doi.org/10.1182/blood-2021-144856

Published: 2021

Journal Articles

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Despina Fotiou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Foteini Theodorakakou, MD, Maria Roussou, MD, Evangelos Terpos, MD PhD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-136248

Published: 2020

Journal Articles

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Despina Fotiou, BMBS, MA, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Panagiotis Malandrakis, MD, Foteini Theodorakakou, MD, Ioanna Dialoupi, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Roussou, MD, Evangelos Terpos, MDPhD, Meletios A. Dimopoulos, MD, Efstathios Kastritis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136323

Published: 2020

Journal Articles

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Efstathios Kastritis, MD, Pantelis Roussakis, MSc, Ioannis V Kostopoulos, PhD, Foteini Theodorakakou, MD, Despina Fotiou, BMBS, MA, Nikolaos Kanellias, MD, Ioanna Dialoupi, MD, Magdalini Migkou, Maria Roussou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Asimina Papanikolaou, MD, Anastasia Gatou, MD, Ourania E. Tsitsilonis, MD PhD, Maria Gavriatopoulou, Evangelos Terpos, MDPhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-137353

Published: 2020

NARROW

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only